RT Journal Article
T1 A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients.
A1 Gómez Rodríguez, Blas José
A1 Castro Laria, Luisa
A1 Argüelles Arias, Federico
A1 Castro Márquez, Cristina
A1 Caunedo Álvarez, Ángel
A1 Romero Gómez, Manuel
AB To evaluate the efficacy and safety of a quadruple regimen (BMTO) of the "3-in-1 capsule" (containing bismuth subcitrate potassium, metronidazole and tetracycline) plus omeprazole in naïve and previously treated patients diagnosed with Helicobacter pylori (H. pylori) infection in the clinical setting in Seville (Spain). This is a prospective study carried out on consecutive patients with a confirmed H. pylori infection and upper gastrointestinal symptoms. After providing their informed consent, the patients were treated for ten days with a 3-in-1 capsule containing bismuth subcitrate potassium (140 mg), metronidazole (125 mg) and tetracycline (125 mg: Pylera®), three capsules four times daily, plus omeprazole (20 or 40 mg) twice daily. Eradication of infection was determined by a negative urea breath test at least 28 days after the end of treatment. A total of 58 consecutive patients were enrolled into this study, two of whom withdrew early due to vomiting on days three and five, respectively. In this cohort, 17 patients (29.3%) had a prior history of medication to treat H. pylori. In the intent-to-treat population, eradication was achieved in 97.6% (40/41) and 82.4% (14/17) of cases in patients treated with BMTO as a first-line or rescue therapy, respectively. At least one adverse event was reported by 28 (48%) patients, mostly mild effects (86%). A ten day treatment with BMTO is an effective and safe strategy to combat confirmed H. pylori infection in patients.
SN 1130-0108
YR 2017
FD 2017
LK http://hdl.handle.net/10668/11305
UL http://hdl.handle.net/10668/11305
LA en
DS RISalud
RD Apr 7, 2025